(Q28346061)

object named as

S R McKeown

0 references

author name string

R Gallagher

0 references

C M Hughes

0 references

M M Murray

0 references

O P Friery

0 references

D G Hirst

British Journal of Cancer

0 references

language of work or name

English

0 references

publication date

17 August 2001

0 references

published in

0 references

volume

0 references

issue

0 references

page(s)

625-9

0 references

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

start time

1 August 2001

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

A direct measurement of the radiation sensitivity of normal mouse bone marrow cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364091

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364091

Human CYP2B6: expression, inducibility and catalytic activities

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364091

DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364091

DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364091

Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364091

Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364091

Hypoxic cells as specific drug targets for chemotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364091

Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364091

Comparative chemosensitivity of exponential- versus plateau-phase cells in both in vitro model systems

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364091

Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364091

AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364091

A new mouse tumor model system (RIF-1) for comparison of end-point studies

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364091

Hypobaric hypoxia: A method for testing bioreductive drugs in vivo

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364091

The dynamics of tumor cords in an irradiated mouse mammary carcinoma with a large hypoxic cell component.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364091

Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364091

The potential of using hyperthermia to eliminate radioresistant hypoxic cells

27 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11506506

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11506506

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Potentiation of cisplatin activity by the bioreductive agent tirapazamine

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11506506